Madrigal Pharmaceuticals Quarterly Balance Sheet
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals financial position
As of Jun 30, 2026, Madrigal Pharmaceuticals reported total assets of $1.24 billion, up 22.6% from a year earlier against total liabilities of $720.9 million. Shareholders' equity stood at $523.7 million, or 42.1% of assets. The company held $292.7 million in cash and equivalents against $340.8 million of debt, a net debt position of $48.1 million.
The current ratio (current assets divided by current liabilities) was 3.20, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.65.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 292.73M | 227.03M | 198.69M | 295.69M | 186.19M | 183.65M | 100.02M | 232.68M | 494.60M | 622.52M | 99.92M | 62.05M |
| Short-Term Investments | 546.03M | 585.74M | 784.87M | 814.05M | 610.83M | 659.42M | 826.23M | 765.94M | 563.20M | 436.55M | 534.22M | 170.30M |
| Receivables | 192.31M | 187.36M | 134.48M | 113.28M | 79.23M | 61.43M | 53.82M | 30.46M | 6.90M | — | 0 | — |
| Inventory | 99.39M | 112.07M | 74.84M | 69.32M | 63.50M | 55.24M | 34.07M | 8.71M | 7.07M | 854.00K | 0 | — |
| Total Current Assets | 1.20B | 1.18B | 1.25B | 1.35B | 1.00B | 987.98M | 1.03B | 1.06B | 1.09B | 1.07B | 637.28M | 235.47M |
| Property, Plant & Equipment | 11.59M | 8.04M | 1.50M | 2.91M | 1.61M | 1.90M | 2.19M | 2.27M | 1.70M | 1.74M | 1.55M | 659.00K |
| Intangible Assets | 7.19M | 7.28M | 7.38M | 7.48M | 4.55M | 4.64M | 4.73M | 4.82M | 4.91M | 5.00M | 0 | — |
| Total Assets | 1.24B | 1.23B | 1.26B | 1.36B | 1.02B | 996.63M | 1.04B | 1.07B | 1.10B | 1.08B | 640.55M | 237.96M |
| Accounts Payable | 34.51M | 60.80M | 48.88M | 44.94M | 37.98M | 42.06M | 43.60M | 45.97M | 8.99M | 21.53M | 28.04M | 16.54M |
| Total Current Liabilities | 374.20M | 338.26M | 310.29M | 391.41M | 196.50M | 167.24M | 169.28M | 177.85M | 125.16M | 114.34M | 118.55M | 99.67M |
| Long-Term Debt | 340.79M | 340.33M | 339.88M | 339.75M | 118.38M | 118.00M | 117.57M | 117.09M | 116.61M | 116.14M | 115.48M | 114.73M |
| Total Liabilities | 720.92M | 683.87M | 656.90M | 736.73M | 319.40M | 285.99M | 287.86M | 296.11M | 242.67M | 231.52M | 235.21M | 215.72M |
| Shareholders' Equity | 523.72M | 543.45M | 602.69M | 625.73M | 695.98M | 710.64M | 754.38M | 777.15M | 857.12M | 850.76M | 405.33M | 22.25M |
| Retained Earnings | -2.24B | -2.18B | -2.09B | -2.03B | -1.92B | -1.88B | -1.80B | -1.74B | -1.64B | -1.48B | -1.34B | -1.22B |
| Total Debt | 340.79M | 340.33M | 339.88M | 339.75M | 118.38M | 118.00M | 117.57M | 117.09M | 116.61M | 116.14M | 115.48M | 114.73M |
| Net Cash (Debt) | 497.96M | 472.44M | 643.68M | 770.00M | 678.65M | 725.06M | 808.68M | 881.54M | 941.19M | 942.93M | 518.65M | 117.62M |
| Shares Outstanding | 23.09M | 23.04M | 22.84M | 22.70M | 22.22M | 22.19M | 22.00M | 21.81M | 19.88M | 19.88M | 19.88M | 18.49M |
This table shows 12 quarterly periods of Madrigal Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow MDGL's reporting calendar. What is a balance sheet?